However, targeting TEML in a more atherosclerosis-specific fashion by modulating specific genes, which are both involved in TEML and responsive to CVD risk factors, such as plasma LDL-cholesterol levels, would be highly desirable.
C ardiovascular diseases (CVDs) remain the leading cause of death worldwide. 1 The primary cause of CVDs is the development of atherosclerosis in larger arteries. Key steps in the formation of atherosclerosis are arterial wall retention of low-density lipoproteins (LDLs), endothelial activation, transendothelial migration of leukocytes (TEML), 2 and generation of foam cells initiating the formation of advanced atherosclerotic plaques. Plasma LDL-lowering drugs, such as statins, have shown to reduce the morbidity and mortality from CVD by enabling atherosclerosis regression. 3, 4 Besides the direct effects of statins, strong evidence suggests that these drugs also possess potent anti-inflammatory properties that contribute to their beneficial effects. 4 In fact, data from several clinical trials indicate that both a reduction in plasma cholesterol and inflammation are needed for preventing disease development suggesting that dual-target therapy would be of great value. 5, 6 TEML is a central, continuous inflammatory step of atherosclerosis development that has gained substantial interest 2 as a putative target to reduce atherosclerosis development. However, targeting TEML is not trivial because this pathway is also crucial for inflammation and immune responses in defense against pathogens. 2 If TEML is severely hampered, side effects, such as opportunistic infections, will occur.
In TEML, adhesion molecules are central for leukocyte adhesion and intercellular guidance of leukocytes. Poliovirus receptor-related 2 (Pvrl2) has not been recognized as one of the traditional TEML genes, but it functions as a cell adhesion molecule in the endothelium. 8 Recently, we found Pvrl2 in the atherosclerotic arterial wall as one of the genes markedly downregulated in response to plasma cholesterol lowering (PCL) in atherosclerosis-prone mice with humanlike plasma cholesterol profile, Ldlr
Apob

100/100
Mttp flox/flox Mx1-Cre. 9, 10 Pvrl2 immediately responded to PCL both in early and mature atherosclerotic lesions and was proposed to be causally related to regression of atherosclerosis. 9 PVRL2, or NECTIN2, encodes a single-pass type I membrane glycoprotein that, as the other nectin members, binds via its intracellular region to an actin filament-binding protein, AF-6/Afadin. This binding is required for nectins to recruit, regulate, and interact with junction proteins such as E-cadherin at adherens junctions and JAM-A at tight junctions. 11 PVRL2 expression has been found in neuronal, epithelial, endothelial, and fibroblastic cells and in many tumors. 12 Besides its well-known role as an entry receptor for viruses, 13 it has also been shown to be involved in breast and ovarian cancers 14 and Alzheimer's disease, 15, 16 as well as being an organizer of Sertoli cell-spermatid junctions in the testis 17 and of synapse formation by neurons.
18
PVRL2 is located on chromosome 19q13.2, close to the apolipoprotein genes APOE, APOC1, APOC2, and APOC4. This locus has previously been associated with the CVD phenotypes, carotid intima-media thickness and coronary artery disease (CAD). 19, 20 To date, little is known about PVRL2 in atherosclerosis except for a recent study in mouse, where Pvrl2 expression in prelesion aortic endothelium was strongly induced by oxidized-LDL stimulus. 21 Two other studies suggest a role for PVRL2 in promoting leukocyte diapedesis during disease development. 22, 23 Given its plasma cholesterol responsiveness and its suggested involvement in TEML, we wanted to determine whether PVRL2 may be a suitable drug target to prevent atherosclerosis development. In this study, the atherogenic role of PVRL2 and TEML was investigated in Pvrl2-deficient mice bred onto an atherosclerosis-prone background with a human-like plasma LDL profile (Pvrl2
) and cross-validated in well-characterized CAD patients using genome-wide RNA expression data.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
PVRL2 Plasma Cholesterol Responsiveness and Its Expression During Atherosclerosis Progression
Previously, we have used a whole-genome expression profiling to identify plasma cholesterol-responsive genes driving atherosclerosis regression at different stages in disease development in Ldlr to immediately respond to PCL both in early (week 30) and mature (week 40) atherosclerosis lesions. The atherosclerotic arterial wall expression of Pvrl2 decreased by 44% and 25% after PCL in early and mature lesions, respectively ( Figure 1A) .
To examine whether the cholesterol responsiveness of PVRL2 in mice also translates to humans, we associated PVRL2 expression in the arterial wall (atherosclerotic and nonatherosclerotic) and blood with plasma cholesterol levels in CAD patients from the STAGE study (Stockholm Atherosclerosis Gene Expression). [24] [25] [26] The STAGE study comprises carefully characterized patients undergoing coronary artery bypass grafting surgery from which global gene expression profiles were obtained from CAD-relevant tissues. Levels of PVRL2 expression in the atherosclerotic arterial wall were found to correlate with plasma cholesterol levels: total cholesterol (r=0.304, P=0.011), LDL-cholesterol (r=0.254, P=0.034), and very LDL-cholesterol (r=0.237, P=0.049; Table 1 ). In contrast, this correlation was not found in the nonatherosclerotic wall or blood (of note, the genome-wide expression data from blood is mainly derived from leukocytes; Table 1 ). Taken together these findings suggest that PVRL2 in humans responds to plasma cholesterol in the activated endothelium, that is, atherosclerotic arterial wall.
Next, we investigated the changes in Pvrl2 expression during atherosclerosis progression in Ldlr −/− Apob 100/100 Mttp flox/flox Mx1-Cre mice in which the development of atherosclerosis has been previously determined. 9, 10 Between week 20 and 30, just before the rapid expansion of atherosclerotic lesions in these mice, we observed a marked increase in Pvrl2 expression by 48% (P=0.032; Figure 1B) . Thereafter, the expression levels decreased. Interestingly, the augmented expression of Pvrl2 coincided with an increased expression of migrating leukocytes into the arterial wall (P=0.032; Figure 1B; P=0.036; Figure I in the online-only Data Supplement), indicating a potential role of PVRL2 in TEML.
PVRL2 Affects Atherosclerosis Development
The plasma cholesterol-responsive effect of PVRL2, its changes in expression during atherosclerosis progression, and proposed role in TEML suggest that PVRL2 might be a suitable target for atherosclerosis prevention. To test this hypothesis, we obtained Pvrl2-deficient mice (Pvrl2 10 Pvrl2 deficiency did not affect plasma cholesterol, triglyceride, glucose levels, or weight at euthanize (Table 2 ). However, after 40 weeks, the lesion area in pinned-out aortas was reduced on average 31% (P=0.038) in Pvrl2 ; Figure 2A ). Next, the atherogenic role of PVRL2 was validated in the CAD cohort, STAGE. [24] [25] [26] Levels of PVRL2 expression in the atherosclerotic arterial wall were found to correlate with the extent of coronary atherosclerosis in hypercholesterolemic patients (Table 1) . No correlation was found when including all patients in the cohort, indicating that high plasma cholesterol levels are required for PVRL2 to act on disease development. No correlations were found in nonatherosclerotic arterial wall or in blood (Table 1) .
Pvrl2 Deficiency Modulates Atherosclerotic Lesion Composition
Next, we assessed the composition of atherosclerotic lesions in aortic root cross sections from Pvrl2 . Statistical significance between 2 groups (9-wk-old mice) was analyzed with Mann-Whitney U test, and statistical significance between 3 groups (41-wk-old mice) was analyzed with 1-way ANOVA and Tukey post hoc. The NIMP-R14-stained area, which includes polymorphonuclear cells, showed a trend toward less staining ( Figure  IIC in the online-only Data Supplement).
To assess whether the decrease in Oil Red O staining in Pvrl2
Apob 100/100 mice could reflect a reduced number of lesion foam cell layers (ie, migrated and lipid-loaded To determine whether the decreased number of macrophages was because of an increased apoptosis or an increase in their proliferation, immunohistological staining with Cleaved Caspase 3 and Ki67 markers was performed. There were no differences in either of the stainings, although there was a tendency to a decreased apoptosis in the Pvrl2-deficient mice ( Figure 2G and 2H). In accordance, no differences were found in necrotic core area ( Figure IIE in the online-only Data Supplement).
Further, histological characteristics of atherosclerotic lesions were used to determine plaque stability scores. 27 Strikingly, plaque morphology changes in terms of the relative content of macrophages and lipids versus collagen and smooth muscle cells in Pvrl2-deficient mice showed 49% (P=0.010) more stable plaques compared with littermate controls ( Figure 2I ).
PVRL2 Colocalizes With Endothelial Cells
To determine the localization of PVRL2, cross sections of the aortic root from 15-week-old Pvrl2
Apob 100/100 mice were costained with cell-type-specific markers (ie, CD31, CD14, and SM22α) and PVRL2. The expression of PVRL2 distinctly overlapped with the endothelial cell marker CD31 ( Figure 3A) . In sections from Pvrl2
Apob 100/100 mice, PVRL2 staining was absent ( Figure 3A) . No overlap was detected between PVRL2 and the macrophage marker CD14 or the smooth muscle cell marker SM22α in the plaques ( Figure 3B ).
To assess that Pvrl2 deficiency does not cause any vascular endothelial phenotype, aortic sections from 15-week-old Pvrl2 We next validated the localization of human PVRL2 by analyzing the gene expression levels from the arterial wall (atherosclerotic and nonatherosclerotic) and blood (ie, leukocytes) from STAGE. [24] [25] [26] PVRL2 was highly expressed in the arterial wall (both atherosclerotic and nonatherosclerotic) and lowly expressed in blood when compared with the mean expression of all array genes in their respective tissues (Figure 4) , supporting that endothelial cells and not leukocytes are the primary source for PVRL2 expression in the atherosclerotic lesions.
Pvrl2 Deficiency Reduces TEML Activity
To determine whether the attenuation in atherosclerosis development in the Pvrl2 −/− mice was because of the suggested decrease in TEML activity, we examined Pvrl2 −/− Ldlr −/− Apob 100/100 mice and littermate controls at 9 to 13 weeks of age, before atherosclerotic lesions have been formed. The 2 groups had equally elevated plasma cholesterol levels ( Table 2) . TEML activity was examined by the creation of dorsal air pouches through subcutaneous injections of air followed by tumor necrosis factor-α injections into the pouch. Twenty-four hours later, leukocyte-containing exudates were extracted and examined by fluorescence-activated cell sorting to investigate the different leukocyte subtypes. 28 Strikingly, the number of migrating leukocytes was decreased by 49% (P=0.047) in Pvrl2-deficient mice compared with littermate controls, a difference mainly driven by reduction in the macrophage and monocyte fractions (−68%, P=0.0007; and −46%, P=0.015, respectively; Figure 5A ), which was not found in the neutrophil or T-cell fraction ( Figure 5A ). This difference was not accounted for by lower levels of circulating leukocytes in Pvrl2-deficient mice ( Figure 5B ) nor by increased migratory properties of Pvrl2-deficient primary blood leukocytes ( Figure 5C ). In addition, silencing Pvrl2 in human umbilical vein endothelial cells did not decrease the adherence of monocytes to the endothelium when compared with control ( Figure IV in the online-only Data Supplement), confirming that PVRL2 is not involved in the adhesion step of the migration process. Jointly our data suggest that the decreased migration of leukocytes in the Pvrl2-deficient mice is caused by decreased TEML activity because of the lack of PVRL2 in endothelial cells. Of note, the expression of Pvrl2 in leukocytes from Pvrl2 +/+ mice was undetectable by quantitative PCR (data not shown).
Discussion
The beneficial effect of cholesterol-lowering drugs for CVD is well established. [29] [30] [31] In addition, clinical trials have shown that their pleiotropic anti-inflammatory effect may also contribute to the favorable outcome. 5, 6 Leukocyte migration across the endothelium is a key feature in atherosclerosis development, leading to downstream cascades of immune and inflammatory reactions which accelerate the disease development. 32 Targeting TEML at sites of vascular inflammation during atherosclerosis development may be beneficial.
PVRL2 is a cell adhesion molecule localized at adherens junctions. 8 Cell-to-cell communication via adherens junctions has been shown to play a key role in the pathogenesis of atherosclerosis. 33, 34 Vascular cell adhesion molecules have been proven to regulate TEML from the circulation to the underlying tissues. The regulation is suggested to occur via a guidance and traction function by communication between different cell adhesion complexes. This enables migrating leukocytes to pass through the endothelial cell junctions during different steps in diapedesis. 35, 36 Using atherosclerosis-prone mice with a genetic switch to lower plasma cholesterol levels (Ldlr
Mttp flox/ flox Mx1-Cre), we first identified the cholesterol responsiveness of Pvrl2. The expression of Pvrl2 decreased immediately in response to PCL. The attenuation in expression levels was present both in early and mature lesions, coinciding with the peak time points of TEML activity in disease development. 2 The reactive effect to plasma cholesterol was also detected in CAD patients of the STAGE cohort, [24] [25] [26] in which expression of PVRL2 in the atherosclerotic arterial wall correlated with plasma cholesterol levels. In contrast, PVRL2 expression in the nonatherosclerotic arterial wall did not correlate with plasma cholesterol. Taken together, this suggests that endothelial PVRL2 only responds to plasma cholesterol levels when the endothelium is activated, as in vascular inflammation and ongoing atherosclerosis. This has also been implied by others: Erbilgin et al 21 identified Pvrl2 to be 1 of 14 genes strongly differentially expressed in transcription profiles from prelesion aortic endothelial cells in hyperlipidemic mice. Endothelial Pvrl2 expression was also shown to be activated by oxidized-LDL in C57BL/6 mice. 21 As to date, little is known about the role of PVRL2 in CVD, but its chromosomal position has been identified as a risk locus for the CVD comorbidities CAD and intimamedia thickness. 19, 20 To determine a possible role of PVRL2 in atherogenesis, we bred Pvrl2-deficient mice onto an atherosclerosis background (Ldlr
) with a plasma lipid profile similar to that of patients with CAD 37, 38 and high LDL-cholesterol levels. En face analyses of aortic lesion area and staining of aortic root cross sections revealed that Pvrl2 deficiency results in less atherosclerotic lesions and improved plaque stability, indicating that PVRL2 would promote progression of atherosclerosis.
PVRL2 clearly colocalized with endothelial cells, which is in agreement with previous findings showing that it exerts its main role in endothelial cells and only has marginal expression in leukocytes. 22, 23 The endothelial location of PVRL2 suggests that the mechanisms by which it regulates atherosclerosis development could be through TEML during disease progression. A possible role of PVRL2 in migration of leukocytes has been postulated in 2 previous studies. 22, 23 PVRL2 was found to transinteract with PVRL3 and thereby promote lymphocyte and monocyte extravasation. 22 Furthermore, endothelial PVRL2 was also demonstrated to interact with the leukocyte surface Apob 100/100 mice. A, Number of gated leukocytes and percentage of leukocyte subtypes migrated to dorsal air pouches from male mice assessed by fluorescence-activated cell sorting of the exudates from 3 individual experiments normalized together (in total, n=8 Pvrl2-deficient mice and n=9 littermate controls). B, White blood cell (WBC) count and leukocyte subtype distribution measured in EDTA blood from equally mixed sex groups using a scil Vet abc Animal Blood Counter (n=6 Pvrl2-deficient mice, and n=8 littermate controls). C, In vitro migration of isolated leukocytes from pooled blood from mixed sex groups (n=9, Pvrl2-deficient mice, 7 males and 2 females; and n=7, littermate controls, 4 males and 3 females) after 3 h stimulation with Mcp-1 (monocyte chemoattractant protein-1) using Boyden chambers. *P<0.05; ***P<0.001. Statistical significance was analyzed by Mann-Whitney U test. Data are presented as mean±SEM. AU indicates arbitrary units; and Pvrl2, poliovirus receptor-related 2.
ligand DNAM-1 (DNAX acessory molecule-1). 23 In addition, PVRL2 closely related receptor, PVR (poliovirus receptor), has been implicated in regulating the movement of leukocytes across the endothelium. 23, 39 In our study, we confirmed that lack of PVRL2 does not have an effect on the adhesion of monocytes to the endothelium. We further investigated how Pvrl2 deficiency affected how leukocytes migrate into an air pouch stimulated by tumor necrosis factor-α. In this model, Pvrl2 deficiency leads to a 49% reduction in leukocyte migration of macrophages and monocytes, a result that is in accordance with the previously mentioned studies. 26 Because the levels of circulating leukocytes and their activity were not different between control and Pvrl2-deficient mice, it suggests that Pvrl2 deficiency inhibits TEML activity leading to more stable and reduced atherosclerotic lesions. Of note, the air pouch model presents some limitations because it mimics a microvascular inflammatory response. To corroborate these findings, a macrovascular model of recruitment such as microbead labeling or adoptive transfer of cells would be of interest. Moreover, to further explore the distinctive role of PVRL2 in TEML during atherosclerosis, an endothelial cell-specific knockout model would be of high relevance.
In conclusion, through its cholesterol-responsive effect and regulatory role in TEML, PVRL2 may be a suitable target to treat atherosclerosis and prevent the formation of unstable plaques. Modulating the expression or functional activity of PVRL2 in the activated endothelium, with, for example, blocking peptides/antibodies or antisense RNA in combination with statins, might be an interesting approach to reduce disease progression without obstructing other essential inflammatory and immune reactions in the body.
